424 related articles for article (PubMed ID: 23588668)
1. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.
Alistar SS; Owens DK; Brandeau ML
PLoS One; 2014; 9(1):e86584. PubMed ID: 24489747
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.
Juusola JL; Brandeau ML; Owens DK; Bendavid E
Ann Intern Med; 2012 Apr; 156(8):541-50. PubMed ID: 22508731
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.
Long EF; Brandeau ML; Owens DK
Ann Intern Med; 2010 Dec; 153(12):778-89. PubMed ID: 21173412
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar SS; Grant PM; Bendavid E
BMC Med; 2014 Mar; 12():46. PubMed ID: 24629217
[TBL] [Abstract][Full Text] [Related]
6. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
Cremin I; Alsallaq R; Dybul M; Piot P; Garnett G; Hallett TB
AIDS; 2013 Jan; 27(3):447-58. PubMed ID: 23296196
[TBL] [Abstract][Full Text] [Related]
7. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
8. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
Verguet S; Stalcup M; Walsh JA
Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
[TBL] [Abstract][Full Text] [Related]
9. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
Bernard CL; Owens DK; Goldhaber-Fiebert JD; Brandeau ML
PLoS Med; 2017 May; 14(5):e1002312. PubMed ID: 28542184
[TBL] [Abstract][Full Text] [Related]
11. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial.
Hayes R; Ayles H; Beyers N; Sabapathy K; Floyd S; Shanaube K; Bock P; Griffith S; Moore A; Watson-Jones D; Fraser C; Vermund SH; Fidler S;
Trials; 2014 Feb; 15():57. PubMed ID: 24524229
[TBL] [Abstract][Full Text] [Related]
12. Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United Kingdom.
Long EF; Mandalia R; Mandalia S; Alistar SS; Beck EJ; Brandeau ML
PLoS One; 2014; 9(4):e95735. PubMed ID: 24763373
[TBL] [Abstract][Full Text] [Related]
13. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.
Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY
Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082
[TBL] [Abstract][Full Text] [Related]
15. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study.
Hu QH; Meyers K; Xu JJ; Chu ZX; Zhang J; Ding HB; Han XX; Jiang YJ; Geng WQ; Shang H
BMC Infect Dis; 2019 Jul; 19(1):663. PubMed ID: 31345169
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa.
Pretorius C; Stover J; Bollinger L; Bacaër N; Williams B
PLoS One; 2010 Nov; 5(11):e13646. PubMed ID: 21079767
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
Williams BG; Abdool Karim SS; Karim QA; Gouws E
J Acquir Immune Defic Syndr; 2011 Oct; 58(2):207-10. PubMed ID: 21654503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
